中国组织工程研究 ›› 2024, Vol. 28 ›› Issue (2): 308-314.doi: 10.12307/2023.875
• 组织构建综述 tissue construction review • 上一篇 下一篇
杨启航1,蒲 锐1,2,陈子扬1,2,冷思逸1,宋永晶1,刘 辉3,杜光友1
收稿日期:
2023-01-03
接受日期:
2023-02-02
出版日期:
2024-01-18
发布日期:
2023-06-30
通讯作者:
杜光友,博士,副教授,硕士生导师,长江大学教育与体育学院,湖北省荆州市 434023
蒲锐,硕士,讲师,长江大学教育与体育学院,湖北省荆州市 434023
作者简介:
杨启航,男,1999年生,湖北省襄阳市人,汉族,长江大学在读硕士,主要从事运动健康促进、运动与慢性病干预研究。
基金资助:
Yang Qihang1, Pu Rui1, 2, Chen Ziyang1, 2, Leng Siyi1, Song Yongjing1, Liu Hui3, Du Guangyou1
Received:
2023-01-03
Accepted:
2023-02-02
Online:
2024-01-18
Published:
2023-06-30
Contact:
Du Guangyou, PhD, Associate professor, Master’s supervisor, College of Education and Sports Sciences, Yangtze University, Jingzhou 434023, Hubei Province, China
Pu Rui, Master, Lecturer, College of Education and Sports Sciences, Yangtze University, Jingzhou 434023, Hubei Province, China; Human Science Laboratory of Exercise, Yangtze University, Jingzhou 434023, Hubei Province, China
About author:
Yang Qihang, Master candidate, College of Education and Sports Sciences, Yangtze University, Jingzhou 434023, Hubei Province, China
Supported by:
摘要:
文题释义:
肠道菌群代谢物:人类肠道内拥有数千种不同的细菌物种与宿主和谐共生,肠道菌群代谢物短链脂肪酸、胆汁酸、脂多糖、氧化三甲胺、中链脂肪酸和色氨酸衍生物等对机体的新陈代谢、肥胖和能量平衡等具有调控作用。
背景:肠道菌群与宿主能量平衡和新陈代谢密切相关。肠道菌群代谢物可调控肥胖的发生发展,可成为防治肥胖新靶点。
目的:总结肠道菌群与肥胖之间的相互作用,以及对肠道菌群代谢物调控肥胖的具体作用机制进行分析,旨在为肥胖的防治提供参考与依据。结果与结论:①肠道菌群与肥胖的发生发展密切相关,如厚壁菌与拟杆菌的比值变化可作为肥胖诊断的生物标记物,并通过短双歧杆菌、乳杆菌和阿克曼氏菌等益生菌定植可延缓肥胖的发生。②肠道菌群主要以肠道菌群代谢物为介导参与对肥胖的调控,如短链脂肪酸可通过调节G蛋白偶联受体41,43和过氧化物酶体增殖物激活受体γ等信号通路调控脂肪生成,进而延缓肥胖的发生发展;胆汁酸可通过促进G蛋白偶联受体5和法尼醇X受体的活化,增加胰岛素敏感性和机体组织的能量消耗;此外,脂多糖、氧化三甲胺、中链脂肪酸和色氨酸衍生物还可通过各种信号通路广泛参与肥胖的发生发展。③同一菌群代谢物在调控肥胖具体过程中因其介导的信号通路不同,进而产生异质性作用,在高脂饮食影响下,乙酸可通过诱导副交感神经系统激活,导致食欲亢进和肝脏胰岛素抵抗,进而加速肥胖的生理病程。
https://orcid.org/0000-0002-8590-3481(杨启航)
中国组织工程研究杂志出版内容重点:组织构建;骨细胞;软骨细胞;细胞培养;成纤维细胞;血管内皮细胞;骨质疏松;组织工程
中图分类号:
杨启航, 蒲 锐, 陈子扬, 冷思逸, 宋永晶, 刘 辉, 杜光友. 肠道菌群代谢物在肥胖调控中的作用与机制[J]. 中国组织工程研究, 2024, 28(2): 308-314.
Yang Qihang, Pu Rui, Chen Ziyang, Leng Siyi, Song Yongjing, Liu Hui, Du Guangyou. Role and mechanism of intestinal flora metabolites in obesity regulation[J]. Chinese Journal of Tissue Engineering Research, 2024, 28(2): 308-314.
[1] JASTREBOFF AM, KOTZ CM, KAHAN S, et al. Obesity as a disease: the obesity society 2018 position statement. Obesity (Silver Spring). 2019;27(1):7-9. [2] BLüHER M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288-298. [3] RINNINELLA E, RAOUL P, CINTONI M, et al. What is the healthy gut microbiota composition? A changing ecosystem across age, environment, diet, and diseases. Microorganisms. 2019;7(1):752-766. [4] ALMEIDA A, MITCHELL AL, BOLAND M, et al. A new genomic blueprint of the human gut microbiota. Nature. 2019;568(7753):499-504. [5] SEGATA N, HAAKE SK, MANNON P, et al. Composition of the adult digestive tract bacterial microbiome based on seven mouth surfaces, tonsils, throat and stool samples. Genome Biol. 2012;13(6):R42. [6] UCHIMURA Y, FUHRER T, LI H, et al. Antibodies set boundaries limiting microbial metabolite penetration and the resultant mammalian host response. Immunity. 2018;49(3):545-559.e5. [7] 钱映,冯月梅,汪艳姣,等.肠道菌群与慢性病关系的研究进展[J].中国微生态学杂志,2022,34(10):1217-1221. [8] BÄCKHED F, DING H, WANG T, et al. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004;101(44):15718-15723. [9] SONNENBURG JL, XU J, LEIP DD, et al. Glycan foraging in vivo by an intestine-adapted bacterial symbiont. Science. 2005;307(5717):1955-1959. [10] TURNBAUGH PJ, LEY RE, MAHOWALD MA, et al. An obesity-associated gut microbiome with increased capacity for energy harvest. Nature. 2006;444(7122): 1027-1031. [11] CAPORASO JG, KUCZYNSKI J, STOMBAUGH J, et al. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010;7(5):335-336. [12] FEI N, ZHAO L. An opportunistic pathogen isolated from the gut of an obese human causes obesity in germfree mice. ISME J. 2013;7(4):880-884. [13] PERRY RJ, PENG L, BARRY NA, et al. Acetate mediates a microbiome-brain-β-cell axis to promote metabolic syndrome. Nature. 2016;534(7606):213-217. [14] LIU R, HONG J, XU X, et al. Gut microbiome and serum metabolome alterations in obesity and after weight-loss intervention. Nat Med. 2017;23(7):859-868. [15] ANHê FF, NACHBAR RT, VARIN TV, et al. Treatment with camu camu (Myrciaria dubia) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice. Gut. 2019;68(3):453-464. [16] DEPOMMIER C, EVERARD A, DRUART C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nat Med. 2019;25(7):1096-1103. [17] JANG HR, PARK HJ, KANG D, et al. A protective mechanism of probiotic Lactobacillus against hepatic steatosis via reducing host intestinal fatty acid absorption. Exp Mol Med. 2019;51(8):1-14. [18] IWAO M, GOTOH K, ARAKAWA M, et al. Supplementation of branched-chain amino acids decreases fat accumulation in the liver through intestinal microbiota-mediated production of acetic acid. Sci Rep. 2020;10(1):18768. [19] ZHANG E, JIN L, WANG Y, et al. Intestinal AMPK modulation of microbiota mediates crosstalk with brown fat to control thermogenesis. Nat Commun. 2022; 13(1):1135. [20] ZHANG Y, GU Y, JIANG J, et al. Stigmasterol attenuates hepatic steatosis in rats by strengthening the intestinal barrier and improving bile acid metabolism. NPJ Sci Food. 2022;6(1):38. [21] LI M, WANG S, LI Y, et al. Gut microbiota-bile acid crosstalk contributes to the rebound weight gain after calorie restriction in mice. Nat Commun. 2022;13(1):2060. [22] LE CHATELIER E, NIELSEN T, QIN J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500(7464):541-546. [23] YAN H, QIN Q, CHEN J, et al. Gut microbiome alterations in patients with visceral obesity based on quantitative computed tomography. Front Cell Infect Microbiol. 2021;11(8)232-262. [24] ZHANG S, DANG Y. Roles of gut microbiota and metabolites in overweight and obesity of children. Front Endocrinol (Lausanne). 2022;13(99):49-70. [25] LEY RE, TURNBAUGH PJ, KLEIN S, et al. Microbial ecology: human gut microbes associated with obesity. Nature. 2006;444(7122):1022-1023. [26] VAISERMAN A, ROMANENKO M, PIVEN L, et al. Differences in the gut Firmicutes to Bacteroidetes ratio across age groups in healthy Ukrainian population. BMC Microbiol. 2020;20(1):221. [27] INDIANI C, RIZZARDI KF, CASTELO PM, et al. Childhood obesity and firmicutes/bacteroidetes ratio in the gut microbiota: a systematic review. Child Obes. 2018; 14(8):501-509. [28] VANDER WYST KB, ORTEGA-SANTOS CP, TOFFOLI SN, et al. Diet, adiposity, and the gut microbiota from infancy to adolescence: a systematic review. Obes Rev. 2021;22(5):e13175. [29] BERVOETS L, VAN HOORENBEECK K, KORTLEVEN I, et al. Differences in gut microbiota composition between obese and lean children: a cross-sectional study. Gut Pathog. 2013;5(1):10. [30] YAN H, FEI N, WU G, et al. Regulated inflammation and lipid metabolism in colon mrna expressions of obese germfree mice responding to enterobacter cloacae b29 combined with the high fat diet. Front Microbiol. 2016;7(17):86-99. [31] LE ROY T, LéCUYER E, CHASSAING B, et al. The intestinal microbiota regulates host cholesterol homeostasis. BMC Biol. 2019;17(1):94. [32] BORGERAAS H, JOHNSON LK, SKATTEBU J, et al. Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. Obes Rev. 2018;19(2):219-232. [33] PATTERSON E, WALL R, LISAI S, et al. Bifidobacterium breve with α-linolenic acid alters the composition, distribution and transcription factor activity associated with metabolism and absorption of fat. Sci Rep. 2017;7(43):30-40. [34] KIM DH, JEONG D, KANG IB, et al. Dual function of Lactobacillus kefiri DH5 in preventing high-fat-diet-induced obesity: direct reduction of cholesterol and upregulation of PPAR-α in adipose tissue. Mol Nutr Food Res. 2017;61(11):46-86. [35] ARAúJO J R, TAZI A, BURLEN-DEFRANOUX O, et al. Fermentation products of commensal bacteria alter enterocyte lipid metabolism. Cell Host Microbe. 2020;27(3):358-375.e7. [36] RODRIGUES V F, ELIAS-OLIVEIRA J, PEREIRA ÍS, et al. Akkermansia muciniphila and gut immune system: a good friendship that attenuates inflammatory bowel disease, obesity, and diabetes. Front Immunol. 2022;13(93):46-95. [37] BASOLO A, HOHENADEL M, ANG Q Y, et al. Effects of underfeeding and oral vancomycin on gut microbiome and nutrient absorption in humans. Nat Med. 2020;26(4):589-598. [38] LONG M, YANG S, LI P, et al. Combined use of C. butyricum Sx-01 and L. salivarius C-1-3 improves intestinal health and reduces the amount of lipids in serum via modulation of gut microbiota in mice. Nutrients. 2018;10(7):152-176. [39] CARVALHO BM, SAAD MJ. Influence of gut microbiota on subclinical inflammation and insulin resistance. Mediators Inflamm. 2013;2013(98):679-674. [40] DAVISON JM, LICKWAR CR, SONG L, et al. Microbiota regulate intestinal epithelial gene expression by suppressing the transcription factor Hepatocyte nuclear factor 4 alpha. Genome Res. 2017;27(7):1195-1206. [41] LAMICHHANE S, SEN P, ALVES MA, et al. Linking gut microbiome and lipid metabolism: moving beyond associations. Metabolites. 2021;11(1):55. [42] CUMMINGS JH, POMARE EW, BRANCH WJ, et al. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut. 1987;28(10):1221-1227. [43] MACFARLANE S, MACFARLANE GT. Regulation of short-chain fatty acid production. Proc Nutr Soc. 2003;62(1):67-72. [44] HE J, ZHANG P, SHEN L, et al. Short-chain fatty acids and their association with signalling pathways in inflammation, glucose and lipid metabolism. Int J Mol Sci. 2020;21(17):6356. [45] ZAMBELL KL, FITCH MD, FLEMING SE. Acetate and butyrate are the major substrates for de novo lipogenesis in rat colonic epithelial cells. J Nutr. 2003;133(11):3509-3515. [46] KINDT A, LIEBISCH G, CLAVEL T, et al. The gut microbiota promotes hepatic fatty acid desaturation and elongation in mice. Nat Commun. 2018;9(1):3760. [47] SHIMIZU H, MASUJIMA Y, USHIRODA C, et al. Dietary short-chain fatty acid intake improves the hepatic metabolic condition via FFAR3. Sci Rep. 2019;9(1):16574. [48] 邓邦利. 钙信号和短链脂肪酸调节糖代谢机制研究[D].天津:天津医科大学,2018. [49] DEN BESTEN G, BLEEKER A, GERDING A, et al. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARγ-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015;64(7):2398-2408. [50] OLANIYI KS, ATUMA CL, SABINARI IW, et al. Acetate-mediated-obestatin modulation attenuates adipose-hepatic dysmetabolism in high fat diet-induced obese rat model. Endocrine. 2022;76(3):558-569. [51] KIMURA I, OZAWA K, INOUE D, et al. The gut microbiota suppresses insulin-mediated fat accumulation via the short-chain fatty acid receptor GPR43. Nat Commun. 2013;4(18):29-42. [52] FROST G, SLEETH ML, SAHURI-ARISOYLU M, et al. The short-chain fatty acid acetate reduces appetite via a central homeostatic mechanism. Nat Commun. 2014;5(36):11-29. [53] FORBES S, STAFFORD S, COOPE G, et al. Selective FFA2 agonism appears to act via intestinal PYY to reduce transit and food intake but does not improve glucose tolerance in mouse models. Diabetes. 2015;64(11):3763-3771. [54] PRIYADARSHINI M, LAYDEN BT. FFAR3 modulates insulin secretion and global gene expression in mouse islets. Islets. 2015;7(2):e1045182. [55] SMITH PM, HOWITT MR, PANIKOV N, et al. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science. 2013;341(6145):569-573. [56] OHIRA H, FUJIOKA Y, KATAGIRI C, et al. Butyrate attenuates inflammation and lipolysis generated by the interaction of adipocytes and macrophages. J Atheroscler Thromb. 2013;20(5):425-442. [57] KIMURA I, INOUE D, HIRANO K, et al. The SCFA receptor GPR43 and energy metabolism. front endocrinol (Lausanne). 2014;5(85):66-79. [58] ZHENG M, YANG X, WU Q, et al. Butyrate attenuates hepatic steatosis induced by a high-fat and fiber-deficient diet via the hepatic GPR41/43-CaMKII/HDAC1-CREB pathway. Mol Nutr Food Res. 2022;e2200597. [59] LI Z, YI CX, KATIRAEI S, et al. Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit. Gut. 2018;67(7):1269-1279. [60] CHáVEZ-TALAVERA O, HAAS J, GRZYCH G, et al. Bile acid alterations in nonalcoholic fatty liver disease, obesity, insulin resistance and type 2 diabetes: what do the human studies tell? Curr Opin Lipidol. 2019;30(3):244-254. [61] TRAUNER M, CLAUDEL T, FICKERT P, et al. Bile acids as regulators of hepatic lipid and glucose metabolism. Digestive Diseases. 2010;28(1):220-224. [62] BHATNAGAR S, DAMRON HA, HILLGARTNER FB. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J Biol Chem. 2009;284(15): 10023-10033. [63] NEAL MD, LEAPHART C, LEVY R, et al. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria across the intestinal barrier. J Immunol. 2006;176(5):3070-3079. [64] VIJAY-KUMAR M, AITKEN JD, CARVALHO FA, et al. Metabolic syndrome and altered gut microbiota in mice lacking Toll-like receptor 5. Science. 2010;328(5975):228-231. [65] CANI PD, AMAR J, IGLESIAS MA, et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes. 2007;56(7):1761-1772. [66] WEISBERG SP, MCCANN D, DESAI M, et al. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest. 2003;112(12):1796-1808. [67] ABDALLAH ISMAIL N, RAGAB SH, ABD ELBAKY A, et al. Frequency of Firmicutes and Bacteroidetes in gut microbiota in obese and normal weight Egyptian children and adults. Arch Med Sci. 2011;7(3):501-507. [68] GOMES AC, HOFFMANN C, MOTA JF. The human gut microbiota: metabolism and perspective in obesity. Gut Microbes. 2018;9(4):308-325. [69] MASUI R, SASAKI M, FUNAKI Y, et al. G protein-coupled receptor 43 moderates gut inflammation through cytokine regulation from mononuclear cells. Inflamm Bowel Dis. 2013;19(13):2848-2856. [70] VINOLO MA, RODRIGUES HG, HATANAKA E, et al. Suppressive effect of short-chain fatty acids on production of proinflammatory mediators by neutrophils. J Nutr Biochem. 2011;22(9):849-855. [71] 李亚梦,魏秋阳,刘明宇,等.肠道菌群及其代谢产物氧化三甲胺与冠心病的关系及相关技术方法的研究进展[J].中国微生态学杂志,2022,34(10):1222-1227. [72] LIU J, LAI L, LIN J, et al. Ranitidine and finasteride inhibit the synthesis and release of trimethylamine N-oxide and mitigates its cardiovascular and renal damage through modulating gut microbiota. Int J Biol Sci. 2020;16(5):790-802. [73] SHIH DM, WANG Z, LEE R, et al. Flavin containing monooxygenase 3 exerts broad effects on glucose and lipid metabolism and atherosclerosis. J Lipid Res. 2015;56(1):22-37. [74] KOETH R A, LAM-GALVEZ BR, KIRSOP J, et al. l-Carnitine in omnivorous diets induces an atherogenic gut microbial pathway in humans. J Clin Invest. 2019; 129(1):373-387. [75] GAO X, LIU X, XU J, et al. Dietary trimethylamine N-oxide exacerbates impaired glucose tolerance in mice fed a high fat diet. J Biosci Bioeng. 2014;118(4):476-481. [76] LIANG X, ZHANG Z, LV Y, et al. Reduction of intestinal trimethylamine by probiotics ameliorated lipid metabolic disorders associated with atherosclerosis. Nutrition. 2020;79-80(11):941-955. [77] REN W, WU Q, DENG L, et al. Simultaneous medium chain fatty acids production and process carbon emissions reduction in a continuous-flow reactor: re-understanding of carbon flow distribution. Environ Res. 2022;212(Pt B):113294. [78] ZHAO J, HU J, MA X. Sodium caprylate improves intestinal mucosal barrier function and antioxidant capacity by altering gut microbial metabolism. Food Funct. 2021;12(20):9750-9762. [79] GREGOR A, AUERNIGG-HASELMAIER S, TRAJANOSKI S, et al. Colonic medium-chain fatty acids act as a source of energy and for colon maintenance but are not utilized to acylate Ghrelin. Nutrients. 2021;13(11):3807. [80] SAM QH, LING H, YEW WS, et al. The divergent immunomodulatory effects of short chain fatty acids and medium chain fatty acids. Int J Mol Sci. 2021;22(12):6453. [81] VAN DE HEIJNING JM, OOSTING A, KEGLER D, et al. An increased dietary supply of medium-chain fatty acids during early weaning in rodents prevents excessive fat accumulation in adulthood. Nutrients. 2017;9(6):631. [82] SZTERK A, OFIARA K, STRUS B, et al. Content of health-promoting fatty acids in commercial sheep, cow and goat cheeses. Foods. 2022;11(8):1116. [83] KITAHARA T, KOYAMA N, MATSUDA J, et al. Antimicrobial activity of saturated fatty acids and fatty amines against methicillin-resistant Staphylococcus aureus. Biol Pharm Bull. 2004;27(9):1321-1326. [84] KRISHNAN S, DING Y, SAEDI N, et al. Gut microbiota-derived tryptophan metabolites modulate inflammatory response in hepatocytes and macrophages. Cell Rep. 2018;23(4):1099-1111. [85] SHESTOPALOV AV, SHATOVA OP, GAPONOV AM, et al. The study of tryptophan metabolite concentrations in blood serum and fecal extracts from obese children. Biomed Khim. 2020;66(6):494-501. [86] OSADCHIY V, LABUS JS, GUPTA A, et al. Correlation of tryptophan metabolites with connectivity of extended central reward network in healthy subjects. PLoS One. 2018;13(8):e0201772. [87] HENAO-MEJIA J, WILLIAMS A, GOFF LA, et al. The microRNA miR-181 is a critical cellular metabolic rheostat essential for NKT cell ontogenesis and lymphocyte development and homeostasis. Immunity. 2013;38(5):984-997. [88] VIRTUE AT, MCCRIGHT SJ, WRIGHT JM, et al. The gut microbiota regulates white adipose tissue inflammation and obesity via a family of microRNAs. Sci Transl Med. 2019;11 (496):eaav1892. |
[1] | 龙 宜, 杨佳明, 叶 花, 钟燕彪, 王茂源. 细胞外囊泡在少肌性肥胖中的作用及机制[J]. 中国组织工程研究, 2024, 28(2): 315-320. |
[2] | 梁家琪, 刘恒旭, 阳金鑫, 杨 椅, 邓旭辉, 谭明健, 罗 炯. 运动与肠道菌健康效益的关系[J]. 中国组织工程研究, 2023, 27(8): 1292-1299. |
[3] | 阮 凌, 王光华, 吴荣平, 晋 战, 吕镇庆, 张 楠, 李寿邦. 运动强度与高脂饮食模型大鼠脂代谢紊乱和氧化应激的相关性[J]. 中国组织工程研究, 2023, 27(8): 1149-1155. |
[4] | 张 艳, 何瑞波, 王庆博, 皮亦华, 陆春敏, 徐传仪, 马 刚, 彭 朋. 不同负荷量有氧运动对肥胖大鼠骨骼肌炎症反应和胰岛素信号途径的影响及机制[J]. 中国组织工程研究, 2023, 27(8): 1237-1244. |
[5] | 李玉娇, 苏坤霞. 高强度耐力运动影响高脂诱导肥胖模型小鼠白色脂肪棕色化相关蛋白的表达[J]. 中国组织工程研究, 2023, 27(5): 707-713. |
[6] | 秦祎雄, 袁子健, 谢山周, 祝英文, 陈明慧, 韩 标, 郭 勇. 茶多酚对脂多糖刺激下成骨细胞增殖分化的影响[J]. 中国组织工程研究, 2023, 27(35): 5665-5669. |
[7] | 张慧宇, 于婧文, 白振军, 李 亮, 穆秉桃, 张金锋, 解佳伟. 雷公藤甲素调节小胶质细胞极化反应保护损伤的神经元[J]. 中国组织工程研究, 2023, 27(33): 5342-5347. |
[8] | 冷思逸, 蒲 锐, 陈子扬, 杨启航, 宋永晶, 刘 辉. 运动干预肠道菌群对自身免疫性疾病的作用[J]. 中国组织工程研究, 2023, 27(32): 5219-5226. |
[9] | 杜晨丹, 都冰丽, 宁 潇, 宗明锐, 李 冰, 武秀萍. 钟基因Bmal1在颞下颌关节骨关节炎中的作用机制[J]. 中国组织工程研究, 2023, 27(32): 5227-5231. |
[10] | 刘官娟, 宋 娜, 霍 花, 罗珊珊, 程余婷, 熊 玥, 洪 伟, 廖 健. 唑来膦酸调控NLRP3信号通路抑制脂多糖诱导的破骨细胞分化[J]. 中国组织工程研究, 2023, 27(29): 4677-4683. |
[11] | 肖 哲, 周术锋, 朱 欢, 李 锋, 胡江平. 肥胖人群微血管反应性的变化及运动干预[J]. 中国组织工程研究, 2023, 27(26): 4223-4230. |
[12] | 孙芳园, 孟佳磊, 马宇慧, 耿 欢, 张 涛. 川芎嗪对脂多糖诱导大鼠心肌细胞炎症及氧化应激的作用[J]. 中国组织工程研究, 2023, 27(20): 3253-3258. |
[13] | 崔振华, 林夏妃, 陈永敏, 林 烨, 李关羽, 宋振华. 针灸与康复疗法干预脑缺血模型大鼠神经功能及肠道菌群的变化[J]. 中国组织工程研究, 2023, 27(17): 2692-2698. |
[14] | 林家煜, 黄惠斌, 梁 波, 陈丽君. 高强度间歇运动肥胖大鼠鸢尾素、瘦素、脂联素和内脏脂肪的变化[J]. 中国组织工程研究, 2022, 26(35): 5583-5588. |
[15] | 生卫北, 熊 奡, 刘 苏, 邓嘉鹏, 翁 鉴, 于 斐, 陈英奇, 曾 晖. 磷酸肌酸改性壳聚糖水凝胶干预大鼠骨髓源性巨噬细胞极化和炎症因子的表达[J]. 中国组织工程研究, 2022, 26(31): 5040-5046. |
1.1.6 检索策略 以PubMed数据库检索策略为例,见图1。
1.1.7 检索文献量 检索文献总数量共4 946篇,其中PubMed数据库
1.3 文献质量评价 通过阅读标题、摘要及关键词对文献进行初步筛选,排除重复研究与纳入标准无关的中英文文献,查阅全文最终保留88篇文献,见图2。
#br#
文题释义:
肠道菌群代谢物:人类肠道内拥有数千种不同的细菌物种与宿主和谐共生,肠道菌群代谢物短链脂肪酸、胆汁酸、脂多糖、氧化三甲胺、中链脂肪酸和色氨酸衍生物等对机体的新陈代谢、肥胖和能量平衡等具有调控作用。肥胖是以机体脂质代谢紊乱和能量失调为特征的一种慢性和复发性疾病[1]。肥胖会提高患2型糖尿病、脂肪肝、高血压和脑卒中等疾病的风险[2]。肥胖的诊疗对人体健康具有重要意义,可降低人体患非传染性疾病风险改善健康状况。近年来随着宏基因组等测序技术在肠道菌群研究中的逐渐应用,发现肠道菌群与肥胖之间存在密切联系,肠道菌群可作为肥胖防治的生物标记物。早期关于肠道菌群的研究主要集中在菌群作为诊断肥胖的生物标记物方向。随着研究深入,研究者们发现肠道菌群及其代谢产物可作为信号调节因子进而参与肥胖的调控。
阅读次数 | ||||||
全文 |
|
|||||
摘要 |
|
|||||